What it's for (Indications)
- Oral terbinafine is primarily indicated for the treatment of onychomycosis (tinea unguium) of the toenail or fingernail due to dermatophytes (e.
- g.
- , Trichophyton rubrum, Trichophyton mentagrophytes).
- This systemic antifungal therapy is considered when topical treatments are ineffective or unsuitable, especially in cases of extensive or severe nail involvement, or when multiple nails are affected.
- It is also approved for the treatment of tinea capitis in pediatric patients, a fungal infection of the scalp that often requires systemic therapy due to its penetration into hair follicles and the surrounding structures.
- The decision to use oral terbinafine should be based on a confirmed diagnosis of dermatophyte infection, typically via mycological examination (KOH smear, fungal culture, or histopathology) to accurately differentiate it from other non-fungal nail conditions that would not respond to antifungal treatment.
- Treatment duration varies depending on the infection site and severity, aiming for complete mycological and clinical cure.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adult patients, the standard dosage for onychomycosis is 250 mg orally once daily. The typical duration of treatment is 6 weeks for fingernail onychomycosis and 12 weeks for toenail onychomycosis. It is important to note that full mycological cure, characterized by the growth of healthy, uninfected nail, may not be clinically apparent until several months after the cessation of therapy due to the inherently slow growth rate of nails. For tinea capitis in pediatric patients, the dosage is weight-based: children weighing less than 25 kg should receive 125 mg once daily; those weighing between 25-35 kg should receive 187.5 mg once daily; and children weighing more than 35 kg should receive 250 mg once daily. The usual duration for tinea capitis is 6 to 8 weeks, though this may vary based on clinical response, severity of infection, and physician discretion. Terbinafine tablets can be taken consistently with or without food. It is crucial for patients to complete the full prescribed course of therapy to maximize efficacy, achieve complete eradication of the fungal infection, and minimize the risk of recurrence or the development of antifungal resistance, even if symptoms appear to improve sooner. |
Safety & Warnings
Common Side Effects
- The most commonly reported adverse reactions associated with oral terbinafine include various gastrointestinal disturbances such as diarrhea, dyspepsia, abdominal pain, nausea, and flatulence.
- Other frequently observed side effects are headache, skin rash, and pruritus (itching).
- A significant and often bothersome side effect is taste disturbance (dysgeusia), which can range from altered taste perception to complete loss of taste (ageusia).
- This taste disturbance can be severe, sometimes prolonged, and in rare cases, even permanent, potentially leading to decreased appetite, unintended weight loss, and reduced quality of life.
- Less common but more serious adverse events include hepatobiliary dysfunction, which can manifest as transient elevated liver enzymes, cholestatic hepatitis, and in severe cases, liver failure requiring transplantation or resulting in death.
- Severe dermatological reactions like Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported.
- Hematologic dyscrasias such as neutropenia, agranulocytosis, pancytopenia, and thrombocytopenia have also occurred.
- Additionally, exacerbation of pre-existing psoriasis or precipitation of lupus erythematosus-like reactions have been observed.
- Patients should be thoroughly counseled on recognizing these symptoms and seeking immediate medical attention if any serious adverse reactions develop.
Serious Warnings
- Black Box Warning: Oral terbinafine does not carry a formal FDA Black Box Warning. However, it is associated with several serious risks that warrant careful consideration, thorough patient monitoring, and explicit counseling, often highlighted as 'Serious Warnings' in its prescribing information. These critical potential adverse effects underscore the importance of thorough patient evaluation and close monitoring throughout the entire treatment course: **Hepatotoxicity:** Cases of liver failure, some leading to liver transplantation or death, have been reported in patients treated with oral terbinafine. Pre-existing liver disease is a strict contraindication, and baseline and periodic monitoring of liver function tests (LFTs) is strongly recommended for all patients. Patients should be advised to discontinue terbinafine and seek immediate medical attention if any signs or symptoms of hepatic dysfunction (e.g., persistent nausea, anorexia, profound fatigue, right upper quadrant pain, dark urine, jaundice, pale stools) occur. **Severe Dermatologic Reactions:** Serious and potentially life-threatening skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported. If a progressive skin rash or other signs of severe dermatological reaction develop, terbinafine should be discontinued immediately. **Hematologic Effects:** Rare but serious cases of neutropenia, agranulocytosis, pancytopenia, and thrombocytopenia have been reported. If patients develop signs or symptoms suggestive of blood dyscrasias (e.g., persistent fever, sore throat, unusual bleeding or bruising), a complete blood count should be promptly performed to investigate the cause.
- Oral terbinafine carries several significant warnings that necessitate careful patient selection, vigilant monitoring, and thorough patient counseling.
- **Hepatotoxicity** is a critical concern, with rare but serious cases of liver failure (some leading to liver transplantation or death) reported in patients treated with oral terbinafine.
- Pre-existing chronic or active liver disease is a contraindication to its use, and baseline as well as periodic monitoring of liver function tests (LFTs) is strongly recommended, especially in patients with pre-existing conditions or those on concomitant hepatotoxic medications.
- Treatment should be immediately discontinued if LFTs significantly elevate or if symptoms indicative of hepatic dysfunction (e.
- g.
- , persistent nausea, anorexia, profound fatigue, vomiting, right upper quadrant pain, jaundice, dark urine, pale stools) develop.
- **Taste and smell disturbances**, including complete loss, are frequent and can be prolonged or permanent, potentially leading to malnutrition and significantly impacting quality of life.
- **Severe dermatologic reactions**, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported; patients should be advised to discontinue therapy and seek immediate medical attention at the first sign of a progressive skin rash.
- **Hematologic abnormalities**, such as neutropenia and pancytopenia, have occurred; complete blood counts should be monitored if unexplained fever, sore throat, or other signs of infection arise.
- Pre-existing **lupus erythematosus** or **psoriasis** may be exacerbated by terbinafine therapy.
- Dosage adjustments are required in patients with **renal impairment** (creatinine clearance <50 mL/min).
- Patients should also be informed about potential drug interactions, particularly with CYP2D6 substrates and inhibitors, as terbinafine is a moderate inhibitor of CYP2D6.
How it Works (Mechanism of Action)
Terbinafine, an allylamine antifungal, exerts its fungicidal action primarily by interfering with the early stage of fungal ergosterol biosynthesis. Ergosterol is a crucial component of the fungal cell membrane that is essential for its structural integrity, fluidity, and proper function. Terbinafine specifically inhibits the enzyme squalene epoxidase, which is a key enzyme located in the fungal cell membrane and plays a vital role in converting squalene to squalene epoxide, an intermediate step in the ergosterol pathway. Inhibition of squalene epoxidase leads to a two-fold deleterious effect on the fungal cell: first, it causes a significant deficiency in ergosterol, thereby compromising the fungal cell membrane's structural integrity, increasing its permeability, and ultimately leading to cell death. Second, the inhibition of squalene epoxidase results in an intracellular accumulation of squalene, which is toxic to the fungal cell. This accumulation disrupts metabolic processes and further contributes to the potent fungicidal effect. Terbinafine is highly selective for fungal squalene epoxidase, showing minimal effect on mammalian squalene epoxidase, thereby contributing to its relatively favorable toxicity profile in human cells compared to fungal cells. Its lipophilic nature allows it to rapidly concentrate in the skin, hair, and nails, providing sustained therapeutic levels at the site of infection.